Skip to main content
Delix Therapeutics

Delix Therapeutics

Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.www.delixtherapeutics.com

Search complete. 3 mentions across 2 episodes found for "Delix Therapeutics".

Sep 21, 2026

The Psychedelic News Feed

The Psychedelic News Feed

Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Sep 21 · 1 Mention

Top 10%
Josh HartmanHOST
15:26
It's dosed the first patients in that phase one study, which is taking place in Australia.
Josh HartmanHOST
15:30
It joins a growing crop of so-called neuroplastogen developers, including Delix Therapeutics, which we reported last month, could be in line to receive fresh investment from various parties, including the large pharmaceutical firm Johnson & Johnson.
Josh HartmanHOST
15:46
Other drug developers working in this segment include Hong Kong-based CSPC Pharmaceutical Group, which is also launching a phase one study of its non-hallucinogenic candidate.
Josh HartmanHOST
15:56
Sticking with companies, Eli Lilly's acquisition of psychedelic drug developer Atai Beckley has officially closed.

Unknown podcast

Episode 9: Engineering Around the Problem - 18-MC, Tabernanthalog & Next-Generation Analogs

Sep 17 · 2 Mentions

speaker_1HOST
29:07
Correct.
speaker_1HOST
29:08
It is currently progressing clinically via a biotechnology company called Delix Therapeutics, operating under the developmental identifiers DLX001 or AAZA154.
speaker_1HOST
29:20
Okay.
speaker_1HOST
29:21
And because of that function-oriented simplification, because they dropped that complex ring, it is vastly simpler to synthesize than Ibogaine or 18MC.

10 MINS LATER

speaker_1HOST
39:31
Until we have large-scale, rigorous, side-by-side human clinical trials comparing a fully psychedelic dose of natural ibogaine with a non-hallucinogenic analog like TBG, the debate remains fundamentally unresolved.
speaker_0HOST
39:44
Which brings us to where the pipeline actually stands today.
speaker_0HOST
39:47
Because while 18MC is shelved and TBG is advancing through Delix Therapeutics, there are other players in the space trying to thread this needle.
speaker_1HOST
39:55
There are.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.